Imugene (ASX:IMU)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Health Check: Imugene goes to the well after reporting more blood cancer ‘cures’
ASX biotechs join global race for cell therapy breakthroughs
Health Check: Don’t dis-May! ASX biotechs record strong year-on-year share gains
Health Check: Biotechs obey the Three Commandments of life sciences
Biocurious: With its ‘molecular Lego’ approach, Arovella is building hope for cancer patients one brick at a time
Health Check: Biotechs recover as peace descends on the FDA – for now
Health Check: Liberation Day spares the global drug sector – for now
Health Check: Bargain hunters flock to 4D Medical’s discounted raising
Health Check: Emvision’s stroke detector takes to the skies
Health Check: Star biotech stocks are going cheap – or cheaper than they were
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
